NCT07339527

EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas

An Open-label, Multicenter, Exploratory Clinical Study of the EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas.

• Status: Not Yet Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, multicenter, open-label, phase Ib/II clinical study to evaluate the safety and efficacy of EZH2 inhibitor Zeprumetostat in combination therapy for patients with relapsed or refractory mature T-cell and NK-cell lymphomas.

Conditions

• Mature T-cell and NK-cell Lymphoma

Interventions

Type	Name	Description
DRUG	Zeprumetostat	350mg, po, bid
DRUG	Golidocitinib	Cohort 1: Golidocitinib: 150mg, po, qd
DRUG	Chidamide	Cohort 2: Chidamide: 20mg, po, biw

Timeline

• Start date: 2026-01-01
• Primary completion: 2028-01-01
• Completion: 2030-01-01
• First posted: 2026-01-14
• Last updated: 2026-01-14